0.00Open0.40Pre Close0 Volume93 Open Interest7.50Strike Price0.00Turnover3072.23%IV43.64%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type0.3158Delta0.1461Gamma13.75Leverage Ratio-5.7947Theta0.0000Rho4.34Eff Leverage0.0003Vega
Monte Rosa Therapeutics Stock Discussion
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
Monte Rosa Therapeutics presented preclinical data at EULAR 2024, showing that MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits rheumatoid arthritis progression in a murine model. The data indicated reduced serum pro-inflammatory cytokines and anti-collagen II autoantibodies. MRT-6160 de...
NEWS
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
Monte Rosa Therapeutics has presented preclinical data on their molecular glue degrader, MRT-6160, at Digestive Disease Week 2024. MRT-6160 targets VAV1, a protein involved in autoimmune and inflammatory diseases like colitis. The study showed significant results, including reduced disease progressi...
No comment yet